Potential therapeutic approach of intravenous immunoglobulin against COVID-19

doi:10.1186/s13223-021-00609-3

Review

. 2021 Oct 9;17(1):105.

doi: 10.1186/s13223-021-00609-3.

Potential therapeutic approach of intravenous immunoglobulin against COVID-19

Zahra Kolahchi¹, Hanye Sohrabi¹, Sara Ekrami Nasab¹, Hesan Jelodari Mamaghani¹, Maryam Keyfari Alamdari¹, Nima Rezaei^{2

3

4}

Affiliations

¹ Students' International Committee of Medical Schools (SICoMS), School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, 14194, Tehran, Iran. rezaei_nima@yahoo.com.
³ Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. rezaei_nima@yahoo.com.
⁴ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. rezaei_nima@yahoo.com.

PMID: 34627384
PMCID: PMC8501925
DOI: 10.1186/s13223-021-00609-3

Review

Potential therapeutic approach of intravenous immunoglobulin against COVID-19

Zahra Kolahchi et al. Allergy Asthma Clin Immunol. 2021.

. 2021 Oct 9;17(1):105.

doi: 10.1186/s13223-021-00609-3.

Authors

Zahra Kolahchi¹, Hanye Sohrabi¹, Sara Ekrami Nasab¹, Hesan Jelodari Mamaghani¹, Maryam Keyfari Alamdari¹, Nima Rezaei^{2

3

4}

Affiliations

¹ Students' International Committee of Medical Schools (SICoMS), School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, 14194, Tehran, Iran. rezaei_nima@yahoo.com.
³ Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. rezaei_nima@yahoo.com.
⁴ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. rezaei_nima@yahoo.com.

PMID: 34627384
PMCID: PMC8501925
DOI: 10.1186/s13223-021-00609-3

Abstract

Since the outbreak of the novel coronavirus disease (COVID-19), the therapeutic and management options to reduce the burden of the COVID-19 disease are under investigation. IVIG therapy is used as an effective treatment for immunodeficient patients and patients with inflammatory or autoimmune conditions. The therapeutic effect of IVIG in COVID-19 patients has been investigated. But, the results are controversial and some studies reported no benefit of IVIG therapy. More clinical trials on the effect of IVIG therapy in COVID-19 patients should be performed to establish a certain conclusion about IVIG effectiveness.

Keywords: Coronavirus disease; Hyperreactivity; Intravenous immunoglobulin; Respiratory syndromes; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Cited by

Mental Healthcare in Pediatrics During the COVID-19 Pandemic: A Call for International Public Health Action.
Aleebrahim-Dehkordi E, Soveyzi F, Deravi N, Saghazadeh A, Rezaei N. Aleebrahim-Dehkordi E, et al. Adv Exp Med Biol. 2024;1458:19-34. doi: 10.1007/978-3-031-61943-4_2. Adv Exp Med Biol. 2024. PMID: 39102187 Review.
A Peek into Pandora's Box: COVID-19 and Neurodegeneration.
Chandra A, Johri A. Chandra A, et al. Brain Sci. 2022 Jan 30;12(2):190. doi: 10.3390/brainsci12020190. Brain Sci. 2022. PMID: 35203953 Free PMC article. Review.
Efficacy of intravenous immunoglobulins (IVIG) in COVID-19 patients: a systematic review and meta-analysis.
Fatemi B, Rezaei S, Peikanpour M, Dastan F, Saffaei A. Fatemi B, et al. Res Pharm Sci. 2023 Jun 1;18(4):346-357. doi: 10.4103/1735-5362.378082. eCollection 2023 Jul-Aug. Res Pharm Sci. 2023. PMID: 37614613 Free PMC article.
The youngest surviving COVID-19 patient: A case report.
Kalani-Moghaddam F, Pouralizadeh N, Pourdowlat G, Sarfarazi-Moghaddam S, Gharib MH, Pakdel M. Kalani-Moghaddam F, et al. Int J Surg Case Rep. 2022 May;94:107065. doi: 10.1016/j.ijscr.2022.107065. Epub 2022 Apr 10. Int J Surg Case Rep. 2022. PMID: 35433235 Free PMC article.
Restraint Stress-Induced Immunosuppression Is Associated with Concurrent Macrophage Pyroptosis Cell Death in Mice.
Li CC, Munalisa R, Lee HY, Lien TS, Chan H, Hung SC, Sun DS, Cheng CF, Chang HH. Li CC, et al. Int J Mol Sci. 2023 Aug 17;24(16):12877. doi: 10.3390/ijms241612877. Int J Mol Sci. 2023. PMID: 37629059 Free PMC article.

See all "Cited by" articles

References

1. Hanaei S, Rezaei N. COVID-19: Developing from an outbreak to a pandemic. Arch Med Res. 2020 doi: 10.1016/j.arcmed.2020.04.021. - DOI - PMC - PubMed
1. WHO. Estimating Mortality from COVID-19. https://www.who.int/news-room/commentaries/detail/estimating-mortality-f.... Accessed 27 Sept 2021.
1. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–e244. doi: 10.1016/S1473-3099(20)30484-9. - DOI - PMC - PubMed
1. Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114. doi: 10.1016/j.virusres.2020.198114. - DOI - PMC - PubMed
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Hanaei S, Rezaei N. COVID-19: Developing from an outbreak to a pandemic. Arch Med Res. 2020 doi: 10.1016/j.arcmed.2020.04.021. - DOI - PMC - PubMed

[2] Hanaei S, Rezaei N. COVID-19: Developing from an outbreak to a pandemic. Arch Med Res. 2020 doi: 10.1016/j.arcmed.2020.04.021. - DOI - PMC - PubMed

[3] WHO. Estimating Mortality from COVID-19. https://www.who.int/news-room/commentaries/detail/estimating-mortality-f.... Accessed 27 Sept 2021.

[4] WHO. Estimating Mortality from COVID-19. https://www.who.int/news-room/commentaries/detail/estimating-mortality-f.... Accessed 27 Sept 2021.

[5] Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–e244. doi: 10.1016/S1473-3099(20)30484-9. - DOI - PMC - PubMed

[6] Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–e244. doi: 10.1016/S1473-3099(20)30484-9. - DOI - PMC - PubMed

[7] Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114. doi: 10.1016/j.virusres.2020.198114. - DOI - PMC - PubMed

[8] Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114. doi: 10.1016/j.virusres.2020.198114. - DOI - PMC - PubMed

[9] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed

[10] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Potential therapeutic approach of intravenous immunoglobulin against COVID-19

Affiliations

Potential therapeutic approach of intravenous immunoglobulin against COVID-19

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources